All In MedTech

Device Trial Radar · NCT04219891

WaveLight® EX500 Excimer Laser System for the Correction of Myopia Using InnovEyes™ in Conjunction With InnovEyes™ Sightmap

Pivotal Trial of WaveLight® EX500 Excimer Laser System for the Correction of Myopia With and Without Astigmatism Using InnovEyes™ in Conjunction With InnovEyes™ Sightmap

Last checked: Nov 20, 2026Latest source record: Apr 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingTitle says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

272

Actual

Start

Mar 9, 2020

Primary completion

Nov 9, 2022

Study completion Nov 9, 2022

Sponsor

Lead sponsor
Alcon ResearchNot on our public-company list
Sponsor type
Industry
First posted
Jan 7, 2020

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and effectiveness of the WaveLight EX500 excimer laser system for the correction of myopia with and without astigmatism using InnovEyes in conjunction with InnovEyes sightmap.

Conditions

  • Myopia

Interventions

  • WaveLight EX500 excimer laser system with InnovEyes sightmapDevice

    FDA approved stationary scanning-spot excimer laser system used during refractive surgery for the treatment of myopia, myopic astigmatism, hyperopia, hyperopic astigmatism, and mixed astigmatism. For this clinical study, the WaveLight EX500 software will be upgraded to include the InnovEyes treatment.

  • LASIKProcedure

    Procedure that reshapes the front part of the eye (cornea) so that light traveling through it is properly focused on the back part of the eye (retina). The procedure will be performed using the WaveLight EX500 excimer laser system and data obtained from the InnovEyes sightmap.

  • InnovEyes sightmapDevice

    Non-contact ophthalmic diagnostic device that captures images of the eye and collects ocular data preoperatively to generate a patient-specific ablation profile for refractive correction surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Eyes With Uncorrected Distance Visual Acuity (UCDVA) of 20/40 or Better (in Eyes With Preoperative Best Corrected Distance Visual Acuity (BCDVA) of 20/20 or Better) at Refractive StabilityTime frame: Preoperative Visit (Day -30 to Day -1), Month 1, Month 3
  2. Percentage of Eyes With Manifest Refractive Spherical Equivalent (MRSE) Within +/- 0.50 Diopter (D) at Refractive StabilityTime frame: Month 1, Month 3
  3. Percentage of Eyes With MRSE Within +/- 1.00 D at Refractive StabilityTime frame: Month 1, Month 3

5 more outcomes with a free account

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Alcon Investigative Site

    San Diego, California

  • Price Vision Group

    Indianapolis, Indiana

  • Alcon Investigative Site

    Chevy Chase, Maryland

6 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.